Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Receivables (2020 - 2025)

InMed Pharmaceuticals has reported Receivables over the past 5 years, most recently at $182967.0 for Q4 2025.

  • For Q4 2025, Receivables fell 30.32% year-over-year to $182967.0; the TTM value through Dec 2025 reached $182967.0, down 30.32%, while the annual FY2025 figure was $465104.0, N/A changed from the prior year.
  • Receivables for Q4 2025 was $182967.0 at InMed Pharmaceuticals, down from $343469.0 in the prior quarter.
  • Over five years, Receivables peaked at $465104.0 in Q2 2025 and troughed at $11919.0 in Q2 2021.
  • A 5-year average of $152742.1 and a median of $76100.5 in 2022 define the central range for Receivables.
  • Biggest five-year swings in Receivables: skyrocketed 340.21% in 2023 and later crashed 30.32% in 2025.
  • Year by year, Receivables stood at $50304.0 in 2021, then soared by 62.31% to $81647.0 in 2022, then fell by 18.21% to $66775.0 in 2023, then surged by 293.21% to $262569.0 in 2024, then tumbled by 30.32% to $182967.0 in 2025.
  • Business Quant data shows Receivables for INM at $182967.0 in Q4 2025, $343469.0 in Q3 2025, and $465104.0 in Q2 2025.